# Caraway Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/caraway-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.carawaytx.com
- Total disclosed funding: $23M
- Latest round: Series A (Nov 26, 2018)
- Investors on record: 6

## About

Rheostat Therapeutics Inc. is a biotechnology company based in the US, focusing on developing innovative therapies targeting neurodegenerative diseases through advanced scientific research.Founded in 2018 and headquartered in Cambridge, US, Rheostat Therapeutics, Inc. develops therapeutic solutions for neurodegenerative disorders. The company has successfully completed 2 deals, with its most recent being on November 21, 2023, when it raised USD 23.00 mn in a Series A funding round, led by investors including AbbVie Biotech Ventures and Amgen Ventures. The CEO, Joshua Resnick, brings significant industry experience, having previously founded other companies in the biotech space.Rheostat Therapeutics specializes in creating therapies for neurodegenerative diseases. Their research is directed toward potential treatments that address critical health challenges faced by patients suffering from conditions such as Alzheimer's and Parkinson's disease, contributing to advancements in healthcare solutions.Rheostat Therapeutics generates revenue through strategic partnerships and funding from investors. The company has raised a total of USD 610.00 mn to date, relying on its innovative research and the potential market demand for its treatments to support financial sustainability.Looking ahead, Rheostat Therapeutics aims to leverage its recent acquisition by Merck & Co., Inc. to enhance its development of treatments for neurodegenerative diseases. With the financial backing from the acquisition, the company is expected to expand its research capabilities and market reach, specifically targeting regions with high healthcare needs. The recent funding will be integral in supporting the launch of new therapies and initiatives aimed at improving patient outcomes in the near future.

## Funding rounds

- Series A, Nov 26, 2018, $23M — Mayo Clinic Ventures, Alexandria Venture Investments, SV Health Investors, Amgen Ventures, AbbVie Ventures, MRL Ventures Fund

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A